📊 ORMP Key Takeaways
Is Oramed Pharmaceuticals Inc.. (ORMP) a Good Investment?
Oramed's reported $64M net income is driven by one-time non-operating gains, masking a fundamentally unprofitable business burning $9.1M in operating cash flow annually on just $2M in revenue. The pharmaceutical company's core operations show severe dysfunction with negative operating margins and negligible gross margins, though a strong balance sheet with $45.9M cash provides near-term runway.
Why Buy Oramed Pharmaceuticals Inc.. Stock? ORMP Key Strengths
- Strong balance sheet with minimal debt ($502.7K liabilities vs $199.7M equity)
- Adequate cash position of $45.9M to fund near-term operations
- Revenue growth of 49.3% YoY from commercialization beginning
- Excellent liquidity ratios (6.98x current ratio) providing financial flexibility
- Significant asset base of $230.9M indicating previous successful capital raises
ORMP Stock Risks: Oramed Pharmaceuticals Inc.. Investment Risks
- Core operations deeply unprofitable with -$15.1M operating loss on $2M revenue base
- Negative operating cash flow of -$9.1M annually indicating unsustainable burn
- Net income appears to be one-time non-recurring gain masking operational reality
- Extraordinarily low 0.7% gross margin suggests pricing or production inefficiencies
- Unclear path to profitability with pharmaceutical company requiring years of R&D and regulatory approval
- At current burn rate, $45.9M cash exhausted within 5 years if operations don't improve
Key Metrics to Watch
- Quarterly revenue growth and path to gross margin profitability
- Operating cash flow trend and operating expense reduction
- Nature and sustainability of non-operating income items creating net income
- R&D pipeline progress and regulatory milestones for pipeline drugs
Oramed Pharmaceuticals Inc.. (ORMP) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.98x current ratio provides a solid financial cushion.
ORMP Profit Margin, ROE & Profitability Analysis
ORMP vs Healthcare Sector: How Oramed Pharmaceuticals Inc.. Compares
How Oramed Pharmaceuticals Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Oramed Pharmaceuticals Inc.. Stock Overvalued? ORMP Valuation Analysis 2026
Based on fundamental analysis, Oramed Pharmaceuticals Inc.. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Oramed Pharmaceuticals Inc.. Balance Sheet: ORMP Debt, Cash & Liquidity
ORMP Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Oramed Pharmaceuticals Inc..'s revenue has declined by 26% over the 5-year period, indicating business contraction. The most recent EPS of $-0.48 indicates the company is currently unprofitable.
ORMP Revenue Growth, EPS Growth & YoY Performance
ORMP Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.0M | -$8.9M | $-0.22 |
| Q2 2025 | $2.0M | $5.6M | $0.13 |
| Q1 2025 | $2.0M | $1.5M | $0.04 |
| Q3 2024 | $1.3M | -$3.2M | $-0.08 |
| Q2 2024 | $674.0K | -$1.2M | $-0.03 |
| Q1 2024 | $666.0K | $1.5M | $0.04 |
| Q3 2023 | $682.0K | -$3.2M | $0.08 |
| Q2 2023 | $674.0K | -$1.2M | $0.03 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Oramed Pharmaceuticals Inc.. Dividends, Buybacks & Capital Allocation
ORMP SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Oramed Pharmaceuticals Inc.. (CIK: 0001176309)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ORMP
What is the AI rating for ORMP?
Oramed Pharmaceuticals Inc.. (ORMP) has an AI rating of SELL with 70% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ORMP's key strengths?
Claude: Strong balance sheet with minimal debt ($502.7K liabilities vs $199.7M equity). Adequate cash position of $45.9M to fund near-term operations.
What are the risks of investing in ORMP?
Claude: Core operations deeply unprofitable with -$15.1M operating loss on $2M revenue base. Negative operating cash flow of -$9.1M annually indicating unsustainable burn.
What is ORMP's revenue and growth?
Oramed Pharmaceuticals Inc.. reported revenue of $2.0M.
Does ORMP pay dividends?
Oramed Pharmaceuticals Inc.. does not currently pay dividends.
Where can I find ORMP SEC filings?
Official SEC filings for Oramed Pharmaceuticals Inc.. (CIK: 0001176309) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ORMP's EPS?
Oramed Pharmaceuticals Inc.. has a diluted EPS of $1.50.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ORMP a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Oramed Pharmaceuticals Inc.. has a SELL rating with 70% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ORMP stock overvalued or undervalued?
Valuation metrics for ORMP: ROE of 32.1% (sector avg: 15%), net margin of 3,202.5% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy ORMP stock in 2026?
Our dual AI analysis gives Oramed Pharmaceuticals Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is ORMP's free cash flow?
Oramed Pharmaceuticals Inc..'s operating cash flow is $-9.1M, with capital expenditures of $9.0K. FCF margin is -457.7%.
How does ORMP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 3,202.5% (avg: 12%), ROE 32.1% (avg: 15%), current ratio 6.98 (avg: 2).
Why is ORMP's return on equity (ROE) so high?
Oramed Pharmaceuticals Inc.. has a return on equity of 32.1%, significantly above the Healthcare sector average of 15%. A high ROE indicates the company is efficient at generating profits from shareholder equity. This is supported by a 3,202.5% net margin.